Nazarian Yaron, Talmi Yoav P, Wolf Michael, Horowitz Zeev, Bedrin Lev, Pfeffer Rephael, Kronenberg Jona
Department of Oral and Maxillofacial Surgery, Barzilai Medical Center, Ashkelon, Israel.
Harefuah. 2007 Feb;146(2):82-4, 168.
Epithelial tumors of the parotid gland comprise 3% of head and neck tumors, and 70%-80% of those are benign. Pleomorphic adenoma is the most common tumor of the parotid gland. Recurrence rate of pleomorphic adenomas (RPAs) following superficial parotidectomy was reported to be as high as 4%, sometimes associated with inadequate surgical treatment of the primary tumor. These tumors have a very slow growth rate, and a ten-year follow-up period is mandatory. RPAs are usually located in the superficial lobe (75%) and are often multinodular. Treatment of RPAs is challenging due to a high risk of facial nerve paresis (7%-50%) and of re-recurrence. Occasionally, post-operative radiotherapy is indicated, but this treatment must be balanced with potential long term risks of secondary malignancy. Medical records of 16 patients with first recurrence and 4 patients with more than one recurrence who were treated in our institution during the past 5 years were reviewed. Five patients were treated by post-operative radiotherapy. Residual or recurrence rate following a second procedure was 15%. Two patients (10%) had permanent paresis of a single branch of the facial nerve. Seventeen out of 20 patients (85%) treated were disease-free after a follow-up period of 5 years. In conclusion, surgical treatment of RPAs is a complex procedure which should be managed by a trained surgical team and can be performed with success and minimal morbidity.
腮腺上皮性肿瘤占头颈部肿瘤的3%,其中70%-80%为良性。多形性腺瘤是腮腺最常见的肿瘤。据报道,腮腺浅叶切除术后多形性腺瘤的复发率高达4%,有时与原发肿瘤手术治疗不充分有关。这些肿瘤生长非常缓慢,必须进行十年的随访。多形性腺瘤通常位于浅叶(75%),且常为多结节性。由于面神经麻痹(7%-50%)和再次复发的风险较高,多形性腺瘤的治疗具有挑战性。偶尔需要术后放疗,但这种治疗必须与继发恶性肿瘤的潜在长期风险相权衡。回顾了我院过去5年收治的16例首次复发和4例多次复发患者的病历。5例患者接受了术后放疗。二次手术后的残留或复发率为15%。2例患者(10%)出现单支面神经永久性麻痹。20例接受治疗的患者中有17例(85%)在5年随访期后无疾病。总之,多形性腺瘤的手术治疗是一个复杂的过程,应由训练有素的手术团队进行管理,并且可以成功实施,并发症最少。